Fig. 3
From: Increased chitotriosidase 1 concentration following nusinersen treatment in spinal muscular atrophy
a Nusinersen dosing regimen according to the prescribing information. Arrows display time points of intrathecal nusinersen administration within the observation period. b Changes of CSF CHIT1 levels from baseline to 14 months, with each bar representing the proportion of patients related to the extent of CSF CHIT1 change. Box and whisker plots show median (vertical line), mean (+), interquartile range (boxes); individual points illustrate values outside of 1.5 × interquartile range (whiskers) from the median; ****p < 0.0001 calculated by Wilcoxon signed-rank test. c Change of CSF CHIT1 levels from baseline to 14 months with each bar representing a single patient. d Correlation between patients’ height and CSF CHIT1 change after 14 months of nusinersen treatment; each icon represents an individual patient; *p < 0.05 calculated by Spearman's rank-order correlation. ΔCHIT1, difference of Chitotriosidase 1 concentration (CHIT1) in cerebrospinal fluid (CSF) between baseline and 14-month follow-up